| 8.54 0 (0%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.98 | 1-year : | 11.66 |
| Resists | First : | 8.55 | Second : | 9.98 |
| Pivot price | 8.52  |
|||
| Supports | First : | 8.49 | Second : | 8.46 |
| MAs | MA(5) : | 8.54 | MA(20) : | 8.52 |
| MA(100) : | 5.13 |
MA(250) : | 2.6 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.4 |
| %K %D | K(14,3) : | 88.8 |
D(3) : | 92.5 |
| RSI | RSI(14): 80.8 | |||
| 52-week | High : | 8.55 | Low : | 0.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CMRX ] has closed below upper band by 31.7%. Bollinger Bands are 96.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.55 - 8.59 | 8.59 - 8.63 |
| Low: | 8.41 - 8.47 | 8.47 - 8.52 |
| Close: | 8.44 - 8.53 | 8.53 - 8.61 |
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Wed, 30 Apr 2025
Why Chimerix Inc. (CMRX) is Surging in 2025 - Yahoo Finance
Tue, 01 Apr 2025
Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025? - Yahoo Finance
Fri, 21 Mar 2025
Chimerix Reports Earnings as $935M Jazz Buyout and FDA Drug Review Advance - Stock Titan
Sun, 09 Mar 2025
Why Chimerix, Inc. (CMRX) Soared Last Week - Yahoo Finance
Fri, 07 Mar 2025
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -44 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 9.38e+007 (%) |
| Held by Institutions | 8.044e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.436e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1 |
| Profit Margin | 0 % |
| Operating Margin | -43 % |
| Return on Assets (ttm) | 73.6 % |
| Return on Equity (ttm) | -33.7 % |
| Qtrly Rev. Growth | 212000 % |
| Gross Profit (p.s.) | 426.25 |
| Sales Per Share | -151.85 |
| EBITDA (p.s.) | -2.29344e+008 |
| Qtrly Earnings Growth | -9.647e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -8.63 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 0 |
| Dividend | 3.39e+006 |
| Forward Dividend | 4.73e+006 |
| Dividend Yield | 39695600% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|